• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Earnings Beat Might Change The Case For Investing In Labcorp Stock (LH)

    Simply Wall St·10/31/2026 17:31:27
    语音播报
    • Labcorp Holdings reported third quarter 2026 sales of US$3,810 million and net income of US$262.8 million, and raised its full year 2026 revenue growth guidance to a range of 5.9% to 6.7%.
    • The business paired higher reported earnings per share with updated guidance, giving investors a clearer view of how current operations are tracking against management's full year plans.
    • We will now look at how Labcorp Holdings' raised full year guidance could influence the existing investment narrative for the business.

    Compare how Labcorp Holdings' guidance shift stacks up against peers by scanning a hand picked group of resilient healthcare stocks with 30 resilient stocks with low risk scores in focus for balance sheet strength.

    Labcorp Holdings Investment Narrative Recap

    For a shareholder in Labcorp Holdings, the key belief is that specialty diagnostics, central lab contracts and productivity programs can offset reimbursement and debt related pressures. The raised 2026 revenue growth guidance to 5.9% to 6.7% suggests current operations are tracking ahead of earlier expectations, which supports that narrative in the near term.

    The most important short term catalyst remains management execution on cost control and mix shift into higher value testing as PAMA cuts approach. The quantified US$100 million risk from PAMA still hangs over margins, so the latest guidance upgrade looks helpful, but does not remove that core concern.

    The partnership to roll out the BD Onclarity HPV Assay through Labcorp Holdings' network looks closely tied to the growth story behind the higher guidance. It directly targets women’s health and extended genotyping, which sit within the specialty diagnostics areas analysts have focused on as potential volume and revenue drivers.

    For you as an investor, the practical question is whether offerings like BD Onclarity can scale fast enough to support the company’s revenue mix before reimbursement pressure tightens. Execution risk sits around integration into clinician programs, health plan initiatives and Labcorp OnDemand while maintaining disciplined spending and managing the existing high leverage.

    What The Consensus Labcorp Holdings Forecasts Assume

    Labcorp Holdings' narrative projects US$16.8b revenue and US$1.4b earnings by 2029. This assumes compound annual revenue growth of 4.7% and an earnings increase of about US$400m from the current level of US$1.0b.

    Uncover why Labcorp Holdings' fair value aligns with its current price.

    NYSE:LH 1-Year Stock Price Chart
    NYSE:LH 1-Year Stock Price Chart

    Exploring Other Perspectives

    Fair value views on Labcorp Holdings from the Simply Wall St Community span from US$354.50 to about US$417.79 across 2 independent estimates, so retail opinions already cover a wide band. When you layer the raised guidance, upcoming PAMA reimbursement risk and the BD Onclarity HPV rollout on top of that, you get very different readings of future resilience. That range is exactly why you may want to review several community viewpoints before committing to your own stance.

    Explore another Labcorp Holdings fair value estimate, including one that suggests it could be worth just $354.50.

    Decide For Yourself

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Labcorp Holdings?

    Once you have a view on Labcorp Holdings, it can help to widen the lens and compare it with other companies that match your risk tolerance and income goals. The Simply Wall St Screener offers several focused lists you can use to stress test your next idea against different financial angles.

    • If capital preservation is your priority, start with resilient companies that score well on risk and balance sheet strength by checking the 30 resilient stocks with low risk scores.
    • For investors hunting for potential value opportunities, use the 18 high quality undiscovered gems to surface lesser known businesses with solid underlying fundamentals.
    • If steady income matters more than price swings, look at companies offering stronger yields and robust payout profiles through the 5 dividend fortresses.